Skip to main content

DataMeds AI, Inc.

corporate_fare Company Profile

DataMeds AI, Inc.

MEDS·NASDAQ·Trade & Services·CIK 0002030763

DataMeds AI, Inc. is a holding company incorporated in 2022, focused on pharmaceuticals and healthcare services. The company aims to create a micro health ecosystem by integrating a pharmacy, wholesale operations, and a technology division that offers a novel platform for hub and clinical services. DataMeds AI, Inc. seeks to improve patient lives and provide solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its patient-centric approach and innovative healthcare applications are designed to shift pharmaceutical care to revolve around the patient across various therapeutic conditions. The company offers a full spectrum of integrated solutions by leveraging its business segments to address access, care coordination, dispensing, delivery, and clinical management of pharmaceutical products, from "specialty-lite" to general maintenance conditions. DataMeds AI, Inc. operates through two wholly owned subsidiaries: Wood Sage LLC and Wellgistics, LLC, and two indirect subsidiaries: Alliance Pharma Solutions LLC d/b/a DelivMeds (now Wellgistics Tech & Hub, LLC) and Community Specialty Pharmacy, LLC (now Wellgistics Pharmacy). In January 2023, the company entered into a Membership Interest Purchase Agreement for the acquisition of Wood Sage, which was completed on June 16, 2024. The acquisition involved paying Mr. Panchal approximately $400,000 in common stock issued at a 20% discount. Wood Sage, a Florida limited liability company formed on June 27, 2014, had no operations to date. In August 2023, Wood Sage acquired 100% of the outstanding membership interests of DelivMeds and Wellgistics Pharmacy.

DataMeds AI, Inc. (NASDAQ:MEDS) is a publicly traded company in the Trade & Services sector. Wiseek monitors MEDS SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$23.34M
Net Income
-$101.27M
Diluted EPS
-$1.43
Op. Cash Flow
-$10.86M
Gross Profit
-$6.43M
Operating Income
-$93.75M
Cash & Equivalents
$42.57K
Total Debt
$23.49M
Debt / Equity
-1.89×
Net Margin
-433.9%
Shares Outstanding
101.31M sh
Source: 10-K · filed 2026-04-24 · accession 0001493152-26-018958
$3.21
Market cap
$8.42M
Volume
1.7K (0.0× avg)
3-mo avg 45.1K
Live data · 2026-08-04 13:47 UTC · Market open

show_chartPrice Chart

Loading chart...

feed MEDS - Latest Insights